PMID- 12730120
OWN - NLM
STAT- MEDLINE
DCOM- 20031002
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 102
IP  - 5
DP  - 2003 Sep 1
TI  - Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed 
      multiple myeloma patients treated with high-dose chemotherapy and single or 
      double autologous transplantation.
PG  - 1588-94
AB  - We used a sensitive real-time reverse transcription-polymerase chain reaction 
      assay to quantify cyclin D1 mRNA levels in bone marrow samples collected at 
      diagnosis from 74 newly diagnosed multiple myeloma (MM) patients who were 
      randomized to undergo either single or double autologous peripheral blood stem 
      cell transplantation as part of first-line therapy for their malignancy. In 46 
      cases, fluorescence in situ hybridization (FISH) analysis and/or conventional 
      cytogenetics were performed to detect chromosome 11 abnormalities. Patients with 
      the t(11;14) or trisomy 11 significantly overexpressed cyclin D1 (P <.0001) in 
      comparison with patients without 11q abnormalities, who had cyclin D1 mRNA levels 
      similar to healthy donors. Overall, 32 (43%) of 74 patients showed cyclin D1 
      overexpression. No difference was found between cyclin D1-positive (group A) and 
      cyclin D1-negative (group B) patients with respect to presenting clinical and 
      laboratory characteristics, including chromosome 13 abnormalities, as well as to 
      response to therapy and overall survival, both of which were calculated on an 
      intent-to-treat basis. Patients who overexpressed cyclin D1 had significantly 
      longer duration of remission in comparison with patients who did not (41 vs 26 
      months, respectively; P =.02). As a result, median event-free survival (EFS) was 
      longer in group A than in group B (33 vs 24 months, respectively; P =.055). We 
      concluded that cyclin D1 overexpression is closely associated with 11q 
      abnormalities and identifies a subset of MM patients who are more likely to have 
      prolonged duration of remission and EFS following autologous transplantation.
FAU - Soverini, Simona
AU  - Soverini S
AD  - Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, 
      Via Massarenti 9-40138 Bologna, Italy.
FAU - Cavo, Michele
AU  - Cavo M
FAU - Cellini, Claudia
AU  - Cellini C
FAU - Terragna, Carolina
AU  - Terragna C
FAU - Zamagni, Elena
AU  - Zamagni E
FAU - Ruggeri, Deborah
AU  - Ruggeri D
FAU - Testoni, Nicoletta
AU  - Testoni N
FAU - Tosi, Patrizia
AU  - Tosi P
FAU - De Vivo, Antonio
AU  - De Vivo A
FAU - Amabile, Marilina
AU  - Amabile M
FAU - Grafone, Tiziana
AU  - Grafone T
FAU - Ottaviani, Emanuela
AU  - Ottaviani E
FAU - Giannini, Barbara
AU  - Giannini B
FAU - Cangini, Delia
AU  - Cangini D
FAU - Bonifazi, Francesca
AU  - Bonifazi F
FAU - Neri, Antonino
AU  - Neri A
FAU - Fabris, Sonia
AU  - Fabris S
FAU - Tura, Sante
AU  - Tura S
FAU - Baccarani, Michele
AU  - Baccarani M
FAU - Martinelli, Giovanni
AU  - Martinelli G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20030501
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 136601-57-5 (Cyclin D1)
RN  - 5J49Q6B70F (Vincristine)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - Q41OR9510P (Melphalan)
RN  - VAD I protocol
SB  - IM
CIN - Blood. 2003 Dec 1;102(12):4245-6; author reply 4246. PMID: 14623774
MH  - Adult
MH  - Antineoplastic Agents, Alkylating/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 13
MH  - Combined Modality Therapy
MH  - Cyclin D1/*genetics
MH  - Cyclophosphamide/administration & dosage
MH  - Dexamethasone/*administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/*administration & dosage
MH  - Female
MH  - Gene Expression
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Melphalan/administration & dosage
MH  - Middle Aged
MH  - *Multiple Myeloma/diagnosis/drug therapy/genetics
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Reverse Transcriptase Polymerase Chain Reaction/standards
MH  - Sensitivity and Specificity
MH  - Vincristine/*administration & dosage
EDAT- 2003/05/06 05:00
MHDA- 2003/10/03 05:00
CRDT- 2003/05/06 05:00
PHST- 2003/05/06 05:00 [pubmed]
PHST- 2003/10/03 05:00 [medline]
PHST- 2003/05/06 05:00 [entrez]
AID - S0006-4971(20)44137-0 [pii]
AID - 10.1182/blood-2002-12-3789 [doi]
PST - ppublish
SO  - Blood. 2003 Sep 1;102(5):1588-94. doi: 10.1182/blood-2002-12-3789. Epub 2003 May 
      1.